Peter Diamandis - 29 Dec 2025 Form 4 Insider Report for Celularity Inc (CELU)

Reporting relationship: Director
Issuer ticker: CELU
Reported as of: 29 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Dec 2025, 16:30:27 UTC
Prior SEC filing: 22 Dec 2025
Next SEC filing: 15 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Peter Diamandis

Key filing fact

Peter Diamandis filed Form 4 for Celularity Inc (CELU) on 30 Dec 2025.

Key facts

This page summarizes Peter Diamandis's Form 4 filing for Celularity Inc (CELU).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 30 Dec 2025, 16:30.

Change

Previous filing in this sequence was filed on 22 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001528288 Primary reporting owner

Diamandis Peter

Relationship: Director
Address: C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK
Signature: /s/ Peter Diamandis
Signature date: 30 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CELU transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +125,000
Change %: +50%
Price: $0.000000
Shares after: 373,765
Date: 29 Dec 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CELU transaction Derivative

Stock Options

Award

Transaction value: $0
Shares: +156,250
Change %: +43%
Price: $0.000000
Shares after: 518,774
Date: 29 Dec 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 156,250
Exercise price: $1.20
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.

Footnote F2

Includes 125,000 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.

Footnote F3

This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.